Loading...
•
Sep 30, 2024
Mirum Pharmaceuticals Q3 2024 Earnings Report
Mirum Pharmaceuticals reported third quarter results and increased 2024 guidance.
Key Takeaways
Mirum Pharmaceuticals reported Q3 2024 global net product sales of $90.3 million, representing an 89% increase compared to Q3 2023. The company increased its 2024 revenue guidance to $330-335 million. Volixibat was granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, and the PDUFA date for chenodiol in CTX is set for December 28, 2024.
Global net product sales reached $90.3 million, an 89% increase year-over-year.
LIVMARLI net sales were $59.1 million for the third quarter.
CHOLBAM and CHENODAL net sales totaled $31.2 million for the third quarter.
Volixibat received breakthrough therapy designation for cholestatic pruritus in PBC.
Revenue by Segment
Forward Guidance
Mirum Pharmaceuticals increased its 2024 revenue guidance to $330-335 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...